Paper Details

  1. Home
  2. Paper Details

Pharmacological effects of vinorelbine in combination with lenvatinib in anaplastic thyroid cancer.

Author: AlìGreta, ArmanettiPaolo, BanchiMarta, BocciGuido, CaymeGinelle J, Di DesideroTeresa, FontaniniGabriella, FranciaGiulio, GentileDaniela, KusmicClaudia, MenichettiLuca, OrlandiPaola

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, N.I.H., ExtramuralResearch funding provided by the NIH to external research institutions and researchers.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Combining vinorelbine and lenvatinib synergistically inhibits anaplastic thyroid cancer cell proliferation and tumor growth. This combination also reduces the expression of ABCB1, a drug efflux transporter, enhancing lenvatinib intracellular concentration.
Paper Details　
Original Abstract of the Article :
Anaplastic thyroid cancer (ATC) is a rare neoplasia with a poor prognosis. Proliferation and apoptosis assays were performed on ATC cell lines (8305C, 8505C) exposed to vinorelbine, lenvatinib, as well as to concomitant combinations. ABCB1, ABCG2 and CSF-1 mRNA expression was evaluated by real time ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://pubmed.ncbi.nlm.nih.gov/32461187

データ提供：米国国立医学図書館（NLM）

A Synergistic Approach to Combating Anaplastic Thyroid Cancer

The world of cancer research is a vast desert, and scientists are constantly searching for new oases of hope. This study delves into the fight against anaplastic thyroid cancer (ATC), a particularly challenging form of cancer known for its aggressive nature. The researchers explored the potential of combining two drugs, vinorelbine and lenvatinib, to create a more potent weapon against ATC. They used a variety of techniques, including cell line studies and animal models, to investigate the effects of these drugs, both individually and in combination. The results of this study are like a refreshing spring in the desert of cancer research. The researchers found that vinorelbine and lenvatinib worked together to create a synergistic antitumor effect, meaning that they were much more effective when used together than they were individually. They also observed a decrease in ABCB1 expression, a protein that can pump drugs out of cells, which could explain why the combination was so effective. This finding is particularly exciting, as it suggests that this combination could be a promising new treatment option for patients with ATC.

A Promising Combination for ATC Treatment

The study revealed that combining vinorelbine and lenvatinib significantly reduced tumor volume in a mouse model of ATC. This suggests that this combination could be a valuable new treatment option for patients with this aggressive cancer.

New Hope for ATC Patients

These findings are a beacon of hope for patients with ATC, who currently have limited treatment options. Further research is needed to confirm these results in clinical trials, but the potential of this combination therapy is undeniable. It could offer a new ray of hope in the desert of this challenging disease.

Dr.Camel's Conclusion

This research offers a glimmer of hope in the vast desert of anaplastic thyroid cancer. The synergistic effect of vinorelbine and lenvatinib, along with the decreased ABCB1 expression, may offer a new treatment option that could improve patient outcomes.

Date :
  1. Date Completed 2021-06-03
  2. Date Revised 2023-11-11
Further Info :

Pubmed ID

32461187

DOI: Digital Object Identifier

NIHMS1683331

Related Literature

Article Analysis
・Effects of lenvatinib
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.